Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 19Kidney Neoplasms 3Urinary Bladder Neoplasms 1Urethral Neoplasms 1Prostatic Neoplasms 1Melanoma 1Margins of Excision 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 7padeliporfin 5Nivolumab 4Everolimus 4Sunitinib 3Sorafenib 3Mitomycin 3fludarabine 2epothilone B 2durvalumab 2cabozantinib 2Ipilimumab 2Cyclophosphamide 2Cisplatin 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2volociximab 1vinflunine 1sipuleucel-T 1sargramostim 1pemigatinib 1palladium-bacteriopheophorbide 1palbociclib 1obinutuzumab 1luprolide acetate gel depot 1lenvatinib 1ixabepilone 1fludarabine phosphate 1enzalutamide 1belzutifan 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Interferon alpha-2 × Genitourinary × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡